Cargando…
Protocol for a type 2 hybrid effectiveness-implementation study expanding, implementing and evaluating electronic health record-integrated patient-reported symptom monitoring in a multisite cancer centre
INTRODUCTION: Cancer symptom monitoring and management interventions can address concerns that may otherwise go undertreated. However, such programmes and their evaluations remain largely limited to trials versus healthcare systemwide applications. We previously developed and piloted an electronic p...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9066503/ https://www.ncbi.nlm.nih.gov/pubmed/35504641 http://dx.doi.org/10.1136/bmjopen-2021-059563 |
_version_ | 1784699813683527680 |
---|---|
author | Garcia, Sofia F Smith, Justin D Kallen, Michael Webster, Kimberly A Lyleroehr, Madison Kircher, Sheetal Bass, Michael Cella, David Penedo, Frank J |
author_facet | Garcia, Sofia F Smith, Justin D Kallen, Michael Webster, Kimberly A Lyleroehr, Madison Kircher, Sheetal Bass, Michael Cella, David Penedo, Frank J |
author_sort | Garcia, Sofia F |
collection | PubMed |
description | INTRODUCTION: Cancer symptom monitoring and management interventions can address concerns that may otherwise go undertreated. However, such programmes and their evaluations remain largely limited to trials versus healthcare systemwide applications. We previously developed and piloted an electronic patient-reported symptom and need assessment (‘cPRO’ for cancer patient-reported outcomes) within the electronic health record (EHR). This study will expand cPRO implementation to medical oncology clinics across a large healthcare system. We will conduct a formal evaluation via a stepped wedge trial with a type 2 hybrid effectiveness-implementation design. METHODS AND ANALYSIS: Aim 1 comprises a mixed method evaluation of cPRO implementation. Adult outpatients will complete cPRO assessments (pain, fatigue, physical function, depression, anxiety and supportive care needs) before medical oncology visits. Results are available in the EHR; severe symptoms and endorsed needs trigger clinician notifications. We will track implementation strategies using the Longitudinal Implementation Strategy Tracking System. Aim 2 will evaluate cPRO’s impact on patient and system outcomes over 12 months via (a) a quality improvement study (n=4000 cases) and (b) a human subjects substudy (n=1000 patients). Aim 2a will evaluate EHR-documented healthcare usage and patient satisfaction. In aim 2b, participating patients will complete patient-reported healthcare utilisation and quality, symptoms and health-related quality of life measures at baseline, 6 and 12 months. We will analyse data using generalised linear mixed models and estimate individual trajectories of patient-reported symptom scores at baseline, 6 and 12 months. Using growth mixture modelling, we will characterise the overall trajectories of each symptom. Aim 3 will identify cPRO implementation facilitators and barriers via mixed methods research gathering feedback from stakeholders. Patients (n=50) will participate in focus groups or interviews. Clinicians and administrators (n=40) will complete surveys to evaluate implementation. We will graphically depict longitudinal implementation survey results and code qualitative data using directed content analysis. ETHICS AND DISSEMINATION: This study was approved by the Northwestern University Institutional Review Board (STU00207807). Findings will be disseminated via local and conference presentations and peer-reviewed journals. TRIAL REGISTRATION NUMBER: NCT04014751; ClinicalTrials.gov. |
format | Online Article Text |
id | pubmed-9066503 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-90665032022-05-12 Protocol for a type 2 hybrid effectiveness-implementation study expanding, implementing and evaluating electronic health record-integrated patient-reported symptom monitoring in a multisite cancer centre Garcia, Sofia F Smith, Justin D Kallen, Michael Webster, Kimberly A Lyleroehr, Madison Kircher, Sheetal Bass, Michael Cella, David Penedo, Frank J BMJ Open Oncology INTRODUCTION: Cancer symptom monitoring and management interventions can address concerns that may otherwise go undertreated. However, such programmes and their evaluations remain largely limited to trials versus healthcare systemwide applications. We previously developed and piloted an electronic patient-reported symptom and need assessment (‘cPRO’ for cancer patient-reported outcomes) within the electronic health record (EHR). This study will expand cPRO implementation to medical oncology clinics across a large healthcare system. We will conduct a formal evaluation via a stepped wedge trial with a type 2 hybrid effectiveness-implementation design. METHODS AND ANALYSIS: Aim 1 comprises a mixed method evaluation of cPRO implementation. Adult outpatients will complete cPRO assessments (pain, fatigue, physical function, depression, anxiety and supportive care needs) before medical oncology visits. Results are available in the EHR; severe symptoms and endorsed needs trigger clinician notifications. We will track implementation strategies using the Longitudinal Implementation Strategy Tracking System. Aim 2 will evaluate cPRO’s impact on patient and system outcomes over 12 months via (a) a quality improvement study (n=4000 cases) and (b) a human subjects substudy (n=1000 patients). Aim 2a will evaluate EHR-documented healthcare usage and patient satisfaction. In aim 2b, participating patients will complete patient-reported healthcare utilisation and quality, symptoms and health-related quality of life measures at baseline, 6 and 12 months. We will analyse data using generalised linear mixed models and estimate individual trajectories of patient-reported symptom scores at baseline, 6 and 12 months. Using growth mixture modelling, we will characterise the overall trajectories of each symptom. Aim 3 will identify cPRO implementation facilitators and barriers via mixed methods research gathering feedback from stakeholders. Patients (n=50) will participate in focus groups or interviews. Clinicians and administrators (n=40) will complete surveys to evaluate implementation. We will graphically depict longitudinal implementation survey results and code qualitative data using directed content analysis. ETHICS AND DISSEMINATION: This study was approved by the Northwestern University Institutional Review Board (STU00207807). Findings will be disseminated via local and conference presentations and peer-reviewed journals. TRIAL REGISTRATION NUMBER: NCT04014751; ClinicalTrials.gov. BMJ Publishing Group 2022-05-03 /pmc/articles/PMC9066503/ /pubmed/35504641 http://dx.doi.org/10.1136/bmjopen-2021-059563 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Oncology Garcia, Sofia F Smith, Justin D Kallen, Michael Webster, Kimberly A Lyleroehr, Madison Kircher, Sheetal Bass, Michael Cella, David Penedo, Frank J Protocol for a type 2 hybrid effectiveness-implementation study expanding, implementing and evaluating electronic health record-integrated patient-reported symptom monitoring in a multisite cancer centre |
title | Protocol for a type 2 hybrid effectiveness-implementation study expanding, implementing and evaluating electronic health record-integrated patient-reported symptom monitoring in a multisite cancer centre |
title_full | Protocol for a type 2 hybrid effectiveness-implementation study expanding, implementing and evaluating electronic health record-integrated patient-reported symptom monitoring in a multisite cancer centre |
title_fullStr | Protocol for a type 2 hybrid effectiveness-implementation study expanding, implementing and evaluating electronic health record-integrated patient-reported symptom monitoring in a multisite cancer centre |
title_full_unstemmed | Protocol for a type 2 hybrid effectiveness-implementation study expanding, implementing and evaluating electronic health record-integrated patient-reported symptom monitoring in a multisite cancer centre |
title_short | Protocol for a type 2 hybrid effectiveness-implementation study expanding, implementing and evaluating electronic health record-integrated patient-reported symptom monitoring in a multisite cancer centre |
title_sort | protocol for a type 2 hybrid effectiveness-implementation study expanding, implementing and evaluating electronic health record-integrated patient-reported symptom monitoring in a multisite cancer centre |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9066503/ https://www.ncbi.nlm.nih.gov/pubmed/35504641 http://dx.doi.org/10.1136/bmjopen-2021-059563 |
work_keys_str_mv | AT garciasofiaf protocolforatype2hybrideffectivenessimplementationstudyexpandingimplementingandevaluatingelectronichealthrecordintegratedpatientreportedsymptommonitoringinamultisitecancercentre AT smithjustind protocolforatype2hybrideffectivenessimplementationstudyexpandingimplementingandevaluatingelectronichealthrecordintegratedpatientreportedsymptommonitoringinamultisitecancercentre AT kallenmichael protocolforatype2hybrideffectivenessimplementationstudyexpandingimplementingandevaluatingelectronichealthrecordintegratedpatientreportedsymptommonitoringinamultisitecancercentre AT websterkimberlya protocolforatype2hybrideffectivenessimplementationstudyexpandingimplementingandevaluatingelectronichealthrecordintegratedpatientreportedsymptommonitoringinamultisitecancercentre AT lyleroehrmadison protocolforatype2hybrideffectivenessimplementationstudyexpandingimplementingandevaluatingelectronichealthrecordintegratedpatientreportedsymptommonitoringinamultisitecancercentre AT kirchersheetal protocolforatype2hybrideffectivenessimplementationstudyexpandingimplementingandevaluatingelectronichealthrecordintegratedpatientreportedsymptommonitoringinamultisitecancercentre AT bassmichael protocolforatype2hybrideffectivenessimplementationstudyexpandingimplementingandevaluatingelectronichealthrecordintegratedpatientreportedsymptommonitoringinamultisitecancercentre AT celladavid protocolforatype2hybrideffectivenessimplementationstudyexpandingimplementingandevaluatingelectronichealthrecordintegratedpatientreportedsymptommonitoringinamultisitecancercentre AT penedofrankj protocolforatype2hybrideffectivenessimplementationstudyexpandingimplementingandevaluatingelectronichealthrecordintegratedpatientreportedsymptommonitoringinamultisitecancercentre |